Compare BJDX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJDX | INM |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.7M |
| IPO Year | 2021 | 2020 |
| Metric | BJDX | INM |
|---|---|---|
| Price | $2.00 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 111.9K | 74.9K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $249,040.00 | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.63 | $0.73 |
| 52 Week High | $10.20 | $7.98 |
| Indicator | BJDX | INM |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 42.45 |
| Support Level | $1.43 | $0.73 |
| Resistance Level | $2.47 | $0.95 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 48.98 | 30.75 |
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.